CA2749817A1 - Procedes de determination d'une reponse de patient par la mesure de l'expression de her-2 - Google Patents

Procedes de determination d'une reponse de patient par la mesure de l'expression de her-2 Download PDF

Info

Publication number
CA2749817A1
CA2749817A1 CA2749817A CA2749817A CA2749817A1 CA 2749817 A1 CA2749817 A1 CA 2749817A1 CA 2749817 A CA2749817 A CA 2749817A CA 2749817 A CA2749817 A CA 2749817A CA 2749817 A1 CA2749817 A1 CA 2749817A1
Authority
CA
Canada
Prior art keywords
homodimers
amount
subject
samples
threshold level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2749817A
Other languages
English (en)
Inventor
Michael Bates
Jennifer W. Cook
Gundo Diedrich
Laurie Goodman
Ali Mukherjee
Gordon Parry
Jeff Sperinde
Stephen John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratory Corp of America Holdings
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42340111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2749817(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Publication of CA2749817A1 publication Critical patent/CA2749817A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des procédés de détermination ou autrement d'évaluation de la réponse d'un patient à un traitement, en particulier, à un traitement contre le cancer. Les procédés comprennent l'analyse d'échantillons pour la présence ou l'absence de marqueurs HER2 seuls ou conjointement avec d'autres biomarqueurs, tels que des marqueurs HER3. Dans certains exemples, on peut déterminer le temps probable de progression en déterminant tout d'abord des patients positifs à HER2 puis en stratifiant ensuite à l'aide de la présence ou de l'absence d'un second biomarqueur (par exemple, marqueurs HER3). De plus, les données peuvent être utilisées pour suivre la réponse d'un patient à un régime de traitement, évaluer le succès attendu du traitement d'un patient à l'aide d'un régime particulier, déterminer les effets d'un régime de traitement ou pour catégoriser un patient afin de créer un groupe homogène pour un essai clinique.
CA2749817A 2009-01-15 2010-01-15 Procedes de determination d'une reponse de patient par la mesure de l'expression de her-2 Abandoned CA2749817A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14502909P 2009-01-15 2009-01-15
US61/145,029 2009-01-15
PCT/US2010/021272 WO2010083463A1 (fr) 2009-01-15 2010-01-15 Procédés de détermination d'une réponse de patient par la mesure de l'expression de her-2

Publications (1)

Publication Number Publication Date
CA2749817A1 true CA2749817A1 (fr) 2010-07-22

Family

ID=42340111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2749817A Abandoned CA2749817A1 (fr) 2009-01-15 2010-01-15 Procedes de determination d'une reponse de patient par la mesure de l'expression de her-2

Country Status (12)

Country Link
US (3) US20100233732A1 (fr)
EP (1) EP2387717B1 (fr)
JP (2) JP2012515353A (fr)
KR (1) KR20110120890A (fr)
CN (1) CN102439452B (fr)
AU (1) AU2010204576A1 (fr)
BR (1) BRPI1007048A2 (fr)
CA (1) CA2749817A1 (fr)
ES (1) ES2526519T3 (fr)
IL (1) IL214067A0 (fr)
SG (1) SG172984A1 (fr)
WO (1) WO2010083463A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
CA2706763C (fr) 2007-11-27 2013-07-30 Laboratory Corporation Of America Holdings Procede ameliore de detection et/ou de quantification d'un analyte dans un echantillon
CA2711843C (fr) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Procedes de diagnostic du her-2
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
CA2749846C (fr) 2009-01-15 2018-08-07 Laboratory Corporation Of America Holdings Procedes permettant de determiner la reponse d'un patient par mesure de her-3
EP2913405B1 (fr) 2010-07-27 2016-11-09 Genomic Health, Inc. Procédé d'utilisation de l'expression génique pour déterminer le pronostic du cancer de la prostate
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP6468838B2 (ja) 2011-05-19 2019-02-13 ラボラトリー コーポレイション オブ アメリカ ホールディングス 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
FR2993668B1 (fr) * 2012-07-17 2015-07-03 Cisbio Bioassays Methode theranostique basee sur la detection de dimeres her2-her2
JP6402173B2 (ja) * 2013-04-05 2018-10-10 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法
CA2965872C (fr) 2014-11-25 2022-02-22 Ventana Medical Systems, Inc. Essai de proximite utilisant la ligature chimique et le transfert d'haptenes
WO2017014694A1 (fr) * 2015-07-23 2017-01-26 National University Of Singapore Wbp2 en tant que facteur de co-pronostic avec her2 pour la stratification de patients pour le traitement
JP2019515252A (ja) 2016-03-15 2019-06-06 ラボラトリー コーポレイション オブ アメリカ ホールディングス 細胞間のタンパク質相互作用を評価する方法
WO2018060301A1 (fr) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Anticorps bispécifiques dirigés contre cd3
JP6922444B2 (ja) * 2016-11-11 2021-08-18 コニカミノルタ株式会社 蛍光ナノ粒子を用いた、病理学的完全奏効（ｐＣＲ）の予測を支援するための検査支援方法
US20210239702A1 (en) * 2018-06-14 2021-08-05 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
KR102317202B1 (ko) * 2018-10-19 2021-10-25 주식회사 프로티나 유방암 재발 예측 방법
KR20230134232A (ko) 2022-03-14 2023-09-21 부산대학교 산학협력단 백금계 항암제에 대한 난소암 환자의 약물 반응성 예측용 다중 바이오마커 조성물 및 이를 이용한 진단방법

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0753065B1 (fr) * 1994-03-29 2003-05-14 Celltech Therapeutics Limited Anticorps contre la selectine e
SE9601676D0 (sv) * 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US6335479B1 (en) * 1998-10-13 2002-01-01 Dai Nippon Printing Co., Ltd. Protective sheet for solar battery module, method of fabricating the same and solar battery module
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6682887B1 (en) * 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US20040248150A1 (en) * 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US7037654B2 (en) * 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US6649351B2 (en) * 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US20030235832A1 (en) * 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US7001725B2 (en) * 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US20030092012A1 (en) * 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
US6673550B2 (en) * 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6162593A (en) * 1999-10-26 2000-12-19 Wyatt; Marion F. Diisopropylbenzene containing solvent and method of developing flexographic printing plates
DE19963849A1 (de) * 1999-12-30 2001-07-12 Giesecke & Devrient Gmbh Datenträger mit gedrucktem Sicherheitselement
US7306904B2 (en) * 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
US6743911B2 (en) * 2000-03-14 2004-06-01 Shell Oil Company Process for the carbonylation of pentenenitrile
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US20030207300A1 (en) * 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US7160735B2 (en) * 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US20040067498A1 (en) * 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
CA2417355A1 (fr) * 2000-08-08 2002-02-14 Aclara Biosciences, Inc. Dosages enzymatiques multiplexes
ES2394293T3 (es) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna contra cánceres que están asociados con el oncogén HER-2/neu
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
CZ20033143A3 (en) * 2001-05-21 2004-04-14 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
HUP0501021A3 (en) * 2001-05-21 2006-06-28 Aclara Biosciences Inc Mountai Methods and compositions for analyzing proteins
AU2002344221A1 (en) * 2001-05-26 2002-12-09 Aclara Biosciences, Inc. Catalytic amplification of multiplexed assay signals
WO2003055439A2 (fr) * 2001-07-18 2003-07-10 The Regents Of The University Of California Antigene cible her2/neu et son utilisation pour stimuler une reponse immunitaire
AU2002319613A1 (en) * 2001-07-19 2003-03-03 Signet Laboratories, Inc. Human tissue specific drug screening procedure
GB2378245A (en) * 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
WO2003033741A1 (fr) * 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Amorce a marque electrophoretique universelle, compositions de sonde et procedes associes
US7045311B2 (en) * 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
US6659577B2 (en) * 2001-12-06 2003-12-09 Hewlett-Packard Development Company, L.P. Dual flat springs for tool-less slide installation
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
EP1478667B1 (fr) * 2002-02-26 2010-09-08 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Anticorps monoclonal anti-tenascine humain
KR20040108655A (ko) * 2002-03-05 2004-12-24 아클라라 바이오사이언시스 인코퍼레이티드 막-결합된 민감제를 사용하는 복합 분석법
EP2799555B1 (fr) * 2002-03-13 2017-02-22 Genomic Health, Inc. Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
WO2003085374A2 (fr) * 2002-04-02 2003-10-16 Aclara Biosciences, Inc. Dosages multiplexes utilisant des marqueurs moleculaires separes par electrophorese
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US7105308B2 (en) * 2002-07-25 2006-09-12 Monogram Biosciences, Inc. Detecting receptor oligomerization
US20040229293A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20090111127A1 (en) * 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US7402397B2 (en) * 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040175765A1 (en) * 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
WO2004010842A2 (fr) * 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Sondes electrophoretiques lipophiles
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
AU2004225439A1 (en) * 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20100291594A1 (en) * 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
WO2005011607A2 (fr) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Traitement des cancers exprimant p95erbb2
CA2535510C (fr) * 2003-08-11 2013-10-15 Monogram Biosciences, Inc. Detection et profilage de complexes moleculaires
WO2005017493A2 (fr) * 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarqueurs contre le cancer
US20050106571A1 (en) * 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
UA94019C2 (ru) * 2004-07-09 2011-04-11 Чугаи Сейяку Кабусики Кайся Антитело, которое специфически связывается с глипиканом 3 (gpc3)
WO2006044748A2 (fr) * 2004-10-15 2006-04-27 Monogram Biosciences, Inc. Predicteurs de reponse pour medicaments specifiques de la voie erbb
JP5188808B2 (ja) * 2004-11-03 2013-04-24 アイリス モレキュラー ダイアグノスティクス， インコーポレイテッド 同種の分析物検出
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US20060212956A1 (en) * 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CN1928563B (zh) * 2005-09-09 2010-04-28 上海张江生物技术有限公司 乳腺癌的免疫组化诊断试剂盒和测试片
CA2706763C (fr) * 2007-11-27 2013-07-30 Laboratory Corporation Of America Holdings Procede ameliore de detection et/ou de quantification d'un analyte dans un echantillon
CN101230390A (zh) * 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法
CA2711843C (fr) * 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Procedes de diagnostic du her-2
SG177252A1 (en) * 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
CA2749846C (fr) * 2009-01-15 2018-08-07 Laboratory Corporation Of America Holdings Procedes permettant de determiner la reponse d'un patient par mesure de her-3

Also Published As

Publication number Publication date
CN102439452B (zh) 2015-04-15
JP2014074724A (ja) 2014-04-24
EP2387717B1 (fr) 2014-12-10
IL214067A0 (en) 2011-08-31
US20140370523A1 (en) 2014-12-18
JP5615986B2 (ja) 2014-10-29
BRPI1007048A2 (pt) 2016-02-10
AU2010204576A1 (en) 2011-09-01
CN102439452A (zh) 2012-05-02
SG172984A1 (en) 2011-08-29
WO2010083463A9 (fr) 2010-12-23
US20170082626A1 (en) 2017-03-23
KR20110120890A (ko) 2011-11-04
JP2012515353A (ja) 2012-07-05
WO2010083463A1 (fr) 2010-07-22
ES2526519T3 (es) 2015-01-13
EP2387717A1 (fr) 2011-11-23
US20100233732A1 (en) 2010-09-16
EP2387717A4 (fr) 2012-09-26

Similar Documents

Publication Publication Date Title
CA2749817A1 (fr) Procedes de determination d'une reponse de patient par la mesure de l'expression de her-2
JP2012515353A5 (fr)
Villaflor et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
AU2004258085B2 (en) Expression profile algorithm and test for cancer prognosis
Sueta et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes?
ES2812105T3 (es) Algoritmo y evaluación del perfil de expresión génica para determinar el pronóstico del cáncer de próstata
Ignatiadis et al. Understanding the molecular basis of histologic grade
Ross Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome
Garczyk et al. AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection
WO2008151072A1 (fr) Test pronostique multigénique pour le cancer du poumon
JP2015530072A (ja) ゲムシタビン療法による乳癌の治療方法
Chen et al. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy
JP2013532489A (ja) 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング
Noske et al. Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
ES2914727T3 (es) Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata
Garufi et al. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Yao et al. Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: A meta-analysis
Rausch et al. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1
Onoda et al. The value of progesterone receptor expression in predicting the recurrence score for hormone-receptor positive invasive breast cancer patients
da Luz et al. The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?
CN114350799A (zh) Htr2c在低级别胶质瘤的预后中的应用
Dancik et al. A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors
CN113943803A (zh) Htr6在乳腺癌的诊断、预后中的应用
Yue et al. RT-qPCR is helpful to distinguish the clinicopathological features of HER2 immunohistochemistry 0 and 1+
Bulut et al. Significance of Neutrophil-Lymphocyte Ratio and Thrombocyte-Lymphocyte Ratio in Predicting Complete Pathological Response in Patients with Local Advanced Breast Cancer.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140708

FZDE Discontinued

Effective date: 20191023

FZDE Discontinued

Effective date: 20191023